Research ArticleCOAGULATION

Disrupting the platelet internal membrane via PI3KC2α inhibition impairs thrombosis independently of canonical platelet activation

See allHide authors and affiliations

Science Translational Medicine  22 Jul 2020:
Vol. 12, Issue 553, eaar8430
DOI: 10.1126/scitranslmed.aar8430

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

PIK-ing the best anticoagulant

Inappropriate or excessive blood clotting is a common problem with potentially severe consequences, including heart attacks and strokes. Although numerous antithrombotic agents are already in clinical use, their application is always a balancing act, weighing the risks of excessive clotting against the risks of excessive anticoagulation and resulting bleeding. By studying the phosphoinositide 3-kinase (PI3K) pathway in platelets, Selvadurai et al. identified an antithrombotic intervention that was effective in human blood samples and in mouse models of thrombosis caused by arterial injury. Unlike established antiplatelet drugs, the experimental compound did not cause excessive bleeding in mouse models, suggesting it as a potential candidate for clinical testing.

View Full Text

Stay Connected to Science Translational Medicine